Ben men 1

NCH93 tumor cells originated from a 64-year-old man suffering from a relapsed anaplastic meningioma (WHO°III) located in the left parieto-occipital region. The tumor sample was first mechanically dissected. Then the resulting cell suspension was cultured in Dulbecco’s minimal Eagle’s medium supplemented with 10% fetal calf serum (Sigma-Aldrich, St. Louis, MO, USA), 2% L-GlutaMAX (Sigma-Aldrich) and 1% Penicillin/Streptomycin (Sigma-Aldrich). Cells were subcultured in a ratio of 1:10 twice a week. Mycoplasma contamination was excluded by 4′,6-diamidino-2-phenylindole staining (Roche). The benign cell line Ben-Men-1 was purchased from DSMZ (Braunschweig, Germany). Cells were grown in the same medium as NCH93, and both were cultured at 37 °C in a humidified environment in a 5% CO₂ atmosphere. Cell lines were authenticated by STR DNA profiling analysis (Leibniz Institute DMSZ, Braunschweig, Germany).

Human benign meningioma cell line Ben-Men-1 and HEK293T were purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany). Ben-Men-1 was originally established from a meningothelial meningioma after surgical tumor resection [55 (link)]. The cells were immortalized by retroviral transduction with human telomerase reverse transcriptase (hTERT) gene [55 (link)].
Ben-Men-1 and HEK293T cells were cultured in Dulbecco's Modified Eagle Medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10 % (v/v) heat-inactivated fetal bovine serum (FBS; Biochrom, Berlin, Germany) and 1 % (w/v) penicillin/streptomycin (P/S; Life Technologies, Carlsbad, CA, USA) at 37 °C and 5 % CO2.